SELLAS Life Sciences Group Financial Statements
NASDAQ: SLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
11.65+0.39 (+3.46%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
SELLAS Life Sciences Group revenue and earnings
SELLAS Life Sciences Group reported a net loss of $26.9 million, compared with a loss of $30.9 million a year earlier. Diluted earnings per share came in at -$0.25.
Summary generated from market data by MetaCap's automated system. Methodology
SELLAS Life Sciences Group income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 1.00M | 7.60M | 1.90M | 0 | — | — | — |
| Revenue growth (YoY) | — | — | -100.00% | -86.84% | +300.00% | — | — | — | — | — |
| Cost of Revenue | 0 | 0 | 0 | 100.00K | 200.00K | 0 | — | — | — | — |
| Gross Profit | — | — | 0 | 900.00K | 7.40M | 1.90M | — | — | — | — |
| Operating Expenses | — | — | 37.87M | 42.85M | 32.69M | 18.88M | — | — | — | 31.87M |
| Research & Development | 16.02M | 19.10M | 24.01M | 20.27M | 15.67M | 9.28M | 7.29M | 8.77M | 6.07M | 11.39M |
| Selling, General & Admin | 12.25M | 12.42M | 13.86M | 12.58M | 11.32M | 9.60M | 9.92M | 12.77M | 15.09M | 4.59M |
| Operating Income | -28.27M | -31.51M | -37.87M | -41.95M | -25.29M | -16.98M | -20.04M | — | -23.04M | -15.99M |
| Other Income (Expense) | 1.41M | 632.00K | 529.00K | 649.00K | 4.36M | 208.00K | -19.37M | -29.05M | -23.50M | 21.01M |
| Pretax Income | -26.86M | -30.88M | -37.34M | -41.30M | -20.94M | -16.77M | -19.37M | -29.05M | -23.50M | -17.68M |
| Income Tax | 0 | 0 | 0 | 0 | -237.00K | -17.00K | -81.00K | -1.38M | 253.00K | 1.00K |
| Net Income | -26.86M | -30.88M | -37.34M | -41.30M | -20.70M | -16.76M | -19.29M | -27.67M | -23.75M | -17.68M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.25 | -0.50 | -1.34 | -2.13 | -1.34 | -2.11 | -10.92 | -157.72 | -10.44 | -18.66 |
| EPS (Diluted) | -0.25 | -0.50 | -1.34 | -2.13 | -1.34 | -2.11 | -10.92 | -157.72 | -10.44 | -18.66 |
| Shares Outstanding (Basic) | 109.05M | 61.20M | 27.78M | 19.40M | 15.48M | 7.98M | 2.56M | 261.54K | 2.34M | 947.40K |
| Shares Outstanding (Diluted) | 109.05M | 61.20M | 27.78M | 19.40M | 15.48M | 7.98M | 2.56M | 261.54K | 2.34M | 947.40K |
| EBITDA | — | — | — | — | — | — | — | — | — | -15.98M |
| Gross Margin | — | — | — | 90.00% | 97.37% | 100.00% | — | — | — | — |
| Operating Margin | — | — | — | -4195.00% | -332.82% | -893.79% | — | — | — | — |
| Net Margin | — | — | — | -4130.10% | -272.36% | -881.95% | — | — | — | — |
This table shows 10 annual periods of SELLAS Life Sciences Group's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow SLS's reporting calendar. What is a income statement?